ALX Oncology CEO sells 2,230 shares at $1.93

ALX ONCOLOGY HOLDINGS INC (ALXO) director and chief executive officer Jason Lettmann reported a sale of 2,230 shares of Common Stock on August 17, 2026 at $1.93 per share.

Rhea-AI Filing Summary

ALX ONCOLOGY HOLDINGS INC (ALXO) director and chief executive officer Jason Lettmann reported a sale of 2,230 shares of Common Stock on August 17, 2026 at $1.93 per share. The shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Following this transaction, he directly owned 294,379 shares, which includes 3,000 shares acquired under the issuer's employee stock purchase plan on June 30, 2026.

Insider Trade Summary

Net Seller: 2,230 shares

Net Sell 1 txn

Insider Lettmann Jason

Role CHIEF EXECUTIVE OFFICER

Sold 2,230 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,230	$1.93	$4K

Holdings After Transaction: Common Stock — 294,379 shares (Direct)

Footnotes (2)

1. F1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
2. F2. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

Key Figures

Shares sold: 2,230 shares Sale price: $1.93 per share Shares owned after transaction: 294,379 shares +1 more

4 metrics

Shares sold 2,230 shares Common Stock sold by Jason Lettmann on August 17, 2026

Sale price $1.93 per share Price for the 2,230 Common Stock shares sold

Shares owned after transaction 294,379 shares Direct Common Stock holdings following the August 17, 2026 sale

ESPP shares included 3,000 shares Shares acquired under the employee stock purchase plan on June 30, 2026

Key Terms

restricted stock units, employee stock purchase plan, beneficial ownership

3 terms

restricted stock units financial

"tax obligations in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

employee stock purchase plan financial

"Includes 3,000 shares acquired under the Issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

beneficial ownership financial

"Following this transaction, he directly owned 294,379 shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ALXO CEO Jason Lettmann report on this Form 4?

Jason Lettmann reported a sale of 2,230 ALXO common shares on August 17, 2026 at $1.93 per share. The sale was made to cover tax obligations arising from vesting restricted stock units, rather than as a discretionary portfolio trade.

How many ALXO shares does Jason Lettmann hold after this reported transaction?

After the reported sale, Jason Lettmann directly holds 294,379 shares of ALX Oncology common stock. This total includes 3,000 shares that were acquired under the company’s employee stock purchase plan on June 30, 2026.

What was the purpose of Jason Lettmann’s ALXO share sale on August 17, 2026?

The 2,230 ALXO shares were sold to satisfy tax obligations related to the vesting of restricted stock units. This indicates the transaction was linked to equity compensation taxation, not described as an independent investment decision or trading strategy.

At what price were the ALXO shares sold in Jason Lettmann’s Form 4 filing?

The 2,230 ALXO common shares were sold at a price of $1.93 per share. This per-share price is reported directly in the Form 4 and applies to the transaction executed on August 17, 2026.

Does the reported ALXO Form 4 involve employee stock purchase plan shares?

The sale itself did not involve ESPP shares, but Lettmann’s post-transaction holdings of 294,379 shares include 3,000 shares acquired through ALX Oncology’s employee stock purchase plan on June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:52 PM EDT Accepted by SEC EDGAR 08/18/2026 - 05:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		2,230	D	$1.93	294,379(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

2. Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.

	/s/ Shelly Wong, by power of attorney	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)